Issue 927: December 9, 2022
 Lavi Erisson, M.D., co-founder and CEO of Gensaic, on using phage as a delivery vector for gene therapies.
|
Issues 924 & 925: November 11 and November 17, 2022
 Mark Kessel Strategic Advisor to the Biopharma Sector, on structured financings for R&D programs in biotech companies and fulfilling the responsibilities of an outside board director in a special two part interview.
|
Issue 922: October 28, 2022
 Daniela Salvemini, Ph.D. William Beaumont Professor and Chair Department of Pharmacology and Physiology Director, Henry and Amelia Nasrallah Center for Neuroscience Saint Louis University School of Medicine, on preventing chemotherapy-induced cognitive impairment.
|
Issue 921: October 21, 2022
 James A. Geraghty Author and Veteran of the Orphan Drug Field, on the frontlines of the orphan drug revolution.
|
Issue 917: September 23, 2022
 Eitan S. Kaplan, Ph.D., Scientific Project and Alliance Manager, the Allen Institute for Brain Science, on getting a comprehensive view of the brain to advance Alzheimer’s research.
|
Issue 916: September 16, 2022
 Anand Parikh, J.D., Chief Executive Officer and Co-Founder, Faeth Therapeutics, Inc., on depriving tumors of the nutrients they need to grow.
|
Issue 915: Septembner 9, 2022
 John T. Schiller, Ph.D., Deputy Chief, Laboratory of Cellular Oncology, National Cancer Institute, NIH, on injecting tumors with a virus to promote robust T-cell tumor suppression.
|
Issue 912: August 19, 2022
 Masanori Watanabe, Scohia Pharma Representative Director, President, CEO and CSO, on aiming to maximize the value of our assets through partnerships.
|
Issue 908: July 22, 2022
 Arthur T. Sands, M.D., Ph.D., President and CEO, Nurix Therapeutics, Inc., on opening up new horizons in oncology treatments.
|
Issue 907: July 15, 2022
 Jesús Martin-Garcia, Chairman, CEO, and Co-Founder, GeNeuro, on targeting pathogenic retroviral proteins.
|
Issue 905: June 24, 2022
 Ping Wang, PhD, DABCC, FAACC, Founder and President, Instanosis Inc., Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, and Director of the Clinical Chemistry Section and Core Laboratory, University of Pennsylvania Perelman School of Medicine, on developing an ultrasensitive, rapid, and portable diagnostics platform.
|
Issue 904: June 17, 2022
 Michael Watson, MB, ChB, Co-founder and CEO, Mevox Limited, on addressing the global lack of an effective mumps vaccine.
|
Issue 902: June 3, 2022
 Stephen Majors, Director, Public Affairs, Alliance for Regenerative Medicine, on developing regulatory and reimbursement standards for gene and cell therapies.
|
Issue 901: May 27, 2022
 John Glasspool, Chief Executive Officer, Anthos Therapeutics, on reducing the risk of thrombosis and the risk of bleeding.
|
Issue 900: May 20, 2022
 Boro Dropulić, Ph.D., Co-founder and Executive Director, Caring Cross, on making gene therapy more affordable and accessible.
|
Issue 896: April 22, 2022
 Chris Hoyt, Chief Executive Officer, KeifeRx, LLC, on triggering autophagy to treat neurodegenerative diseases.
|
Issue 894: April 1, 2022
 David J. Arthur, Chief Executive Officer, Salarius Pharmaceuticals, Inc., on developing anti-cancer programs in protein inhibition and protein degradation.
|
Issue 893: March 25, 2022
 Nate Gross, M.D., Co-Founder and Chief Strategy Officer, Doximity, on a digital platform tailored to the needs of doctors.
|
Issue 892: March 18, 2022
 Omid Veiseh, Ph.D., Assistant Professor of Bioengineering and CPRIT Scholar in Cancer Research, Rice University, on localized administration of cytokine-producing cells to eradicate tumors.
|
Issue 891: March 11, 2022
 Tim Guilliams, Ph.D., Co-Founder and Chief Executive, Healx, on combining AI with drug discovery expertise to treat rare diseases.
|
Issue 889: February 25, 2022
 Seiji Fujioka, Representative Director, Nitto Denko Avecia Inc., on growing alongside the nucleic acid medicine industry with a “Niche Top” strategy.
|
Issue 888: February 18, 2022
 James Sapirstein, Chief Executive Officer, First Wave Biopharma, on developing treatments for gastrointestinal disorders.
|
Issue 884: January 21, 2022
 Lane Weaver, Ph.D., Head of Strategy and Business Development, Novome Biotechnologies, Inc., on engineering bacteria in the gut microbiome to treat disease.
|
Issue 880: December 17, 2021
 Lisa Ricciardi, Chief Executive Officer, Cognition Therapeutics, Inc., on targeting the sigma-2 receptor for CNS and ophthalmic disorders.
|
Issue 878: December 3, 2021
 Jennifer Buell, Ph.D., Chief Executive Officer, MiNK Therapeutics, on developing novel off-the-shelf cellular therapies.
|
Issue 877: November 19, 2021
 Aaron Sato, Ph.D., Chief Scientific Officer, Twist Bioscience Corporation, on making antibody discovery faster and more efficient.
|
Issue 875: November 5, 2021
 Alessio Fasano, M.D., Director of the Center for Celiac Research and Treatment, Director of the Mucosal Immunology and Biology Research Center, and Division Chief of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, on uncovering the role of the microbiome in inflammatory diseases.
|
Issue 873: October 15, 2021
 Brian D. Gulbransen, Ph.D., Associate Professor of Physiology, Michigan State University, on exploring the functional roles of enteric glia.
|
Issue 871: October 1, 2021
 Thanh Do, Ph.D., Assistant Professor, Department of Chemistry, the University of Tennessee, FCDI, on the relationship between migraine headaches and type 2 diabetes.
|
Issue 870: September 24, 2021
 Mariko Tosu, Ph.D., Chairman, Braizon Therapeutics, on finding intel in the field of brain disease treatments.
|
Issue 869: September 17, 2021
 Takeshi Yamamoto, President and CEO, FCDI, on progress toward commercialization of regenerative medicine through a broad range of stem cell licenses.
|
Issue 868: September 10, 2021
 Alexis M. Stranahan, Ph.D., Associate Professor, Department of Neuroscience and Regenerative Medicine, Medical College of Georgia at Augusta University, on how beige fat slows cognitive decline.
|
Issue 866: August 27, 2021
 Matthew Stoudt, Co-Founder and CEO, AppliedVR, on using virtual reality to help patients manage chronic pain.
|
Issue 865: August 20, 2021
 David Kelleher, Co-Founder and CEO, 4G Clinical, on making clinical trials faster and more efficient.
|
Issue 864: August 13, 2021
 Eef Schimmelpennink, President and Chief Executive Officer, LENZ Therapeutics, on developing a treatment for presbyopia.
|
Issue 856: June 18, 2021
 Steven Basta, CEO, Mahana Therapeutics, Inc., on a prescription digital therapeutic for irritable bowel syndrome.
|
Issue 854: June 4, 2021
 Chase Coffman, Ph.D., CEO and Co-Founder, Electrofi, on using protein formulations to deliver biologics through simple injections.
|
Issue 853: May 28, 2021
  Kazuhiko Yamamoto, Co-founder and Director, BioPalette, and Kiyokazu Iwata, Business Development Manager, BioPalette, on developing biotherapeutics through base-editing of bacteria.
|
Issue 851: May 14, 2021
 Sean A. McCarthy, D. Phil., President, CEO, and Chairman, CytomX Therapeutics, on engineering cancer therapeutics to avoid healthy tissue.
|
Issue 849: April 30, 2021
 Per Hellsund, President and CEO, Cybrexa Therapeutics, on exploiting the acidity of tumors to deliver toxic payloads.
|
Issue 848: April 23, 2021
 Fumihiko Urano, M.D., Ph.D., Professor of Internal Medicine and Pathology, University of Washington School of Medicine, and Founder of CURE4WOLFRAM, on focusing on gene therapy development as a treatment for optic atrophy.
|
Issue 846: April 9, 2021
 Aurélie Grienenberger, Ph.D., Chief Business Officer, Eligo Bioscience, on precisely targeting the microbiome.
|
Issue 844: March 26, 2021
 Angela M. Reiersen, M.D., M.P.E., Associate Professor of Psychiatry, Washington University in St. Louis, on a repurposed drug showing efficacy in COVID-19 pateints.
|
Issue 843: March 12, 2021
 Samuel Bakhoum, M.D., Ph.D., Assistant Member (Professor), Memorial Sloan Kettering Cancer Center, on targeting an untapped vulnerability of cancer cells.
|
Issue 841: February 26, 2021
 Makoto Nakanishi, MD., Ph.D., Professor, Division of Cancer Cell Biology, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, on the effects of GLS1 enzyme inhibition on controlling and improving aging.
|
Issue 839: February 12, 2021
 Charles K. Fisher, Ph.D., Co-Founder and CEO, Unlearn.AI, on creating more efficient clinical trials with digital twins.
|
Issue 836: January 22, 2021
 Peter Anthony Campochiaro, M.D., Director, Retinal Cell and Molecular Laboratory, Johns Hopkins University School of Medicine, on a better alternative to viral vectors for ocular gene therapy.
|
Issue 832: December 18, 2020
 Mortimer Poncz, M.D., Chief of the Division of Hematology, Children’s Hospital of Philadelphia, on a novel treatment approach for sepsis.
|
Issue 831: December 11, 2020
 Paul Garofolo, President and Chief Executive Officer, Locus Biosciences, on a new platform for targeting bacteria.
|
Issue 826: October 23, 2020
 Giovanni Traverso, M.B., B.Chir., Ph.D., Associate Physician, Brigham and Women’s Hospital, on lining the small intestine to modulate drug delivery.
|
Issue 821: September 18, 2020
 Anthony P. Mack, Founding Chairman and CEO, Virpax Pharmaceuticals, on developing non-addictive treatments for pain management.
|
Issue 817: August 21, 2020
 Greg Merril, CEO and Co-Founder, Adaptive Phage Therapeutics, on developing the potential for phage therapy.
|
Issue 814: July 31, 2020
 Takanori Kanai, M.D., Ph.D., Professor of Gastroenterology, Keio University School of Medicine, on elucidating a new mechanism of intestinal environment maintenance via vagus nerve reflexes.
|
Issue 813: July 24, 2020
 James Patterson, M.B., Ph.D., Founder, Auxolytic, on a novel safety switch for cell therapies.
|
Issue 803: May 8, 2020
 Fumihiko Urano, M.D., Ph.D., Professor of Internal Medicine and Pathology, University of Washington School of Medicine, on curing diabetes in mice with β cells derived from gene-edited iPS cells.
|
Issue 797: March 20, 2020
 Matt Coffey, Ph.D., Co-founder, President and Chief Executive Officer, Oncolytics Biotech Inc., on triggering an immune response against cancer with an oncolytic virus.
|
Issue 795: March 6, 2020
 Evan Feinberg, Ph.D., CEO and Co-founder, Genesis Therapeutics, on using artificial intelligence and medicinal chemistry expertise to design optimized compounds.
|
Issue 794: February 28, 2020
 Takuya Takahashi, MD. PhD, Professor of Physiology, Graduate School of Medicine, Yokohama City University, on imaging ampa receptors in human brains.
|
Issue 793: February 21, 2020
 Vikas Sinha, Co-Founder and Chief Financial Officer, ElevateBio LLC, on building state-of-the-art production facilities for cell and gene therapies.
|
Issue 792: February 14, 2020
 Jennifer Radin, Ph.D., Senior Staff Scientist, Scripps Research Translational Institute, on using data from wearable sensors to track influenza.
|
Issue 788: January 17, 2020
 Julie Fleshman, JD, MBA, President and CEO, the Pancreatic Cancer Action Network, on a platform for quickly and efficiently testing new pancreatic cancer treatments.
|
Issue 783: December 6, 2019
 Stephan Lammel, Ph.D., Assistant Professor of Neurobiology, Department of Molecular & Cell Biology University of California, Berkeley, on identifying the biology underlying specific symptoms of depression.
|
Issue 782: November 22, 2019
 Josep Bassaganya-Riera, DVM, Ph.D., Chairman, President, and CEO, Landos Biopharma, Inc., on using novel metabolic pathways to treat autoimmune diseases.
|
Issue 781: November 15, 2019
 Michael Solomon, Ph.D., Chief Executive Officer, Ribometrix. Inc., on targeting the 3D structure of RNA to reach intractable targets.
|
Issue 780: November 8, 2019
 Rob Etherington, President and CEO, Clene Nanomedicine, Inc., on addressing bioenergetic loss in neurodegenerative diseases.
|
Issue 778: October 25, 2019
 Haitao Hu, Ph.D., Assistant Professor, Microbiology & Immunology, University of Texas Medical Branch, on small molecule induced epigenetic suppression of HIV.
|
Issue 775: October 4, 2019
 Laura Towart Bandak, Founder and CEO, My Personal Therapeutics, on using fruit flies to screen for personalized cancer treatments.
|
Issue 774: September 27, 2019
 Othman Laraki, Co-Founder and CEO, Color, on providing genetic information at scale for low cost.
|
Issue 773: September 20, 2019
 Albert Garcia-Romeu, Ph.D., Instructor in Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, on exploring the therapeutic potential of psilocybin.
|
Issue 772: September 13, 2019
 Amit Kumar, Ph.D., Chairman, President and CEO, Anixa Biosciences, on the development of a vaccine designed to prevent triple-negative breast cancer.
|
Issue 770: August 30, 2019
 Karl Bergman, CEO, Elypta, on metabolic biomarkers as a tool for cancer detection.
|
Issue 769: August 23, 2019
 Adam P. Croft. MRCP, Ph.D., NIHR Academic Clinical Lecturer in Rheumatology, Institute of Inflammation and Ageing, University of Birmingham and Queen Elizabeth Hospital, on identifying drivers of inflammation and joint damage in arthritis.
|
Issue 767: August 9, 2019
 David H. Donabedian, Ph.D., Co-founder and CEO, Axial Biotherapeutics, on focusing on the gut-brain axis for neurological diseases and beyond.
|
Issue 765: July 26, 2019
 Daniel S. Kohane, M.D., Ph.D., Senior Associate in Critical Care; Director, Laboratory for Biomaterials and Drug Delivery Boston Children’s Hopital, and Professor of Anesthesiology, Harvard Medical School, on creating a safe and long-lasting local anesthetic.
|
Issue 764: July 19, 2019
 S. Roy Kimura, Ph.D., Co-founder and CEO, Modulus Discovery, Inc., on discovering revolutionary treatments through virtual pharma.
|
Issue 761: June 21, 2019
 John Didsbury, Ph.D., Founder and CEO, T3D Therapeutics, Inc., on correcting glucose metabolism to treat Alzheimer’s disease.
|
Issue 760: June 14, 2019
 Miguel A. Pappolla, M.D., Ph.D., Professor of Neurology, University of Texas Medical Branch, on making a connection between insulin resistance and fibromyalgia.
|
Issue 758: May 31, 2019
 Andrew A. Radin, CEO and Co-Founder, twoXAR, on separating interesting work from hype in AI-based drug discovery.
|
Issue 757: May 24, 2019
 Anthony Slonim, MD, DrPH, President and Chief Executive Officer, Renown Health, on creating a data warehouse for population health on a grand scale.
|
Issue 755: May 10, 2019
 Berislav V. Zlokovic, M.D., Ph.D., Director of the Zilkha Neurogenetic Institute and Professor and Chair of the Department of Physiology & Neuroscience, Keck School of Medicine, University of Southern California, on reducing beta amyloid accumulation with 3K3A-APC.
|
Issue 753: April 26, 2019
 Mir Imran, Chairman and CEO, Rani Therapeutics, on devising a pill to deliver biologics.
|
Issue 748: March 22, 2019
 Alain Vicari, D.V.M., Ph.D., CEO and Co-founder, Calypso Biotech, on targeting IL-15 for eosinophilic esophagitis.
|
Issue 744: February 15, 2019
 Philippe P. Calais, Pharm. D., Ph.D., Chief Executive Office, CohBar, Inc., on mitochondria-based therapeutics to treat age-related diseases.
|
Issue 742: February 1, 2019
 Jason M. Peters, Ph.D., Assistant Professor, University of Wisconsin–Madison School of Pharmacy, on understanding gene function in diverse bacteria using Mobile-CRISPRi.
|
Issue 739: January 11, 2019
 Zhen Gu, Ph.D., Professor, Department of Bioengineering and the California NanoSystems Institute, University of California, Los Angeles, on inhibiting cancer recurrence and metastasis after surgery.
|
Issue 735: December 7, 2018
 Nader Z. Pourhassan, Ph.D., President and CEO, CytoDyn Inc., on blocking CCR5 in HIV, oncology, and autoimmune diseases.
|
Issue 734: November 30, 2018
 Edward Cox, Chief Executive Officer, Dthera Sciences, on triggering faint memories to reduce agitation and depression.
|
Issue 733: November 16, 2018
 Benjamin A. Plog, Ph.D., CCenter for Translational Neuromedicine, University of Rochester, on using the glymphatic system to deliver drugs deep into the brain.
|
Issue 732: November 9, 2018
 C. Boyd Clarke, Executive Chairman, FluGen, Inc., on preventing influenza virus replication.
|
Issue 730: October 26, 2018
 Tanaka Masato, M.D., Professor, Laboratory of Immune Regulation, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, on discovering monocytes limiting new inflammation that emerge in inflammation recovery.
|
Issue 729: October 19, 2018
 George Tetz, M.D., Ph.D., CEO of the Human Microbiology Institute, on bacteriophages implicated in triggering Parkinson’s disease.
|
Issue 726: September 28, 2018
  Christopher Heise, Ph.D., Associate Director, Genentech, and Peter Smith, Ph.D., Scientist, Genentech, on developing effective new compounds for attacking Gram-negative bacteria.
|
|
Issue 721: August 24, 2018
 Yochi Slonim, Founder and CEO, Anima Biotech, on modulating the production of proteins to treat disease.
|
Issue 720: August 17, 2018
 Misti Ushio, Ph.D., Chief Executive Officer, TARA Biosystems, on engineering mature cardiac tissue for high-throughput applications.
|
Issue 717: July 20, 2018
 Mike Romanos, Ph.D., Co-founder and Chief Executive Officer, Microbiotica Limited, on characterizing the microbiome to create bacteria as therapeutics.
|
Issue 716: July 13, 2018
 Yasuhiko Idaka, Representative Director, Yakushin Co., Ltd., on how pharmaceutical companies should compete in the rapidly changing Japanese market.
|
Issue 713: June 15, 2018
 Takuya Takahashi, M.D., Professor, Department of Physiology, Yokohama City University, on discovering compounds promoting plastic change in the brain.
|
Issue 711: June 1, 2018
 Peter Kirk, Chief Executive Officer, SERMO, on a platform for doctors to share knowledge with each other.
|
Issue 709: May 18, 2018
 Paul Wotton, Ph.D., Chief Executive Officer, Sigilon Therapeutics, on implanting encapsulated cells to treat chronic diseases.
|
Issue 706: April 27, 2018
 Art Krieg, M.D., Founder and CEO, Checkmate Pharmaceuticals, on synergistic therapy to enhance responses to checkpoint inhibitors.
|
Issue 704: April 13, 2018
 Wendy S. Rubinstein, M.D., Ph.D., Deputy Medical Director, CancerLinQ LLC, on learning from real-world data to improve cancer care.
|
Issue 703: April 6, 2018
 Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences, Inc., on modulating the microbiome with consortia of bacteria to treat disease.
|
Issue 702: March 29, 2018
 Edward Giniger, Ph.D., Senior Investigator, National Institute of Neurological Disorders and Stroke, on premature aging in neurodegenerative diseases.
|
Issue 697: February 23, 2018
 Jean-Simon Diallo, Ph.D., Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, on inhibiting NF-κB to enhance the effectiveness of oncolytic viral therapy.
|
Issue 696: February 16, 2018
 Thomas G. Evans, M.D., Chief Executive Officer, Vaccitech Limited, on developing a universal influenza vaccine.
|
Issue 693: January 26, 2018
 Steve Carchedi, Chief Executive Officer, Apexian Pharmaceuticals, Inc., on targeting tumors while protecting neurons.
|
Issue 692: January 19, 2018
 Scott Koenig, M.D., Ph.D., President and CEO, MacroGenics, Inc., on dampening B cell activation without depleting B cells.
|
Issue 691: January 12, 2018
 Masahisa Ikeda, Shearman & Sterling, on people as the key to the global expansion of Japanese companies.
|
Issue 689: December 22, 2017
 David Kita, Ph.D., Co-Founder and Vice President of R&D, Verseon Corporation, on modeling a more diverse chemical space for drug discovery.
|
Issue 686: December 1, 2017
 Alice Zhang, Chief Executive Officer and Co-founder, Verge Genomics, on an integrated approach to accelerate drug discovery.
|
Issue 682: October 27, 2017
 Kevin Outterson, Executive Director, CARB-X, on accelerating R&D in new antibiotics.
|
Issue 681: October 20, 2017
 Lucas Nivon, Ph.D., Chief Executive Officer, Cyrus Biotechnology, Inc., on bringing the power of Rosetta to a broad base of users.
|
Issue 679: October 6, 2017
 John Sullivan-Bolyai, M.D., Chief Medical Officer, ContraVir Pharmaceuticals, Inc., on developing combination treatments for the hepatitis B virus.
|
Issue 678: September 29, 2017
 Sean F. Brady, Ph. D., Evnin Associate Professor and Head, Laboratory of Genetically Encoded Small Molecules, Rockefeller University, on exploring potential interactions between the microbiome and human cells.
|
Issue 677: September 22, 2017
 Vishwanath R. Lingappa, M.D., Ph.D., Chief Executive Officer, Prosetta Biosciences, Inc., on targeting aberrant assembly machines.
|
Issue 675: September 8, 2017
 Robert C. Doebele, M.D., Ph.D., Associate Professor, University of Colorado Anschutz Medical Campus, on using depth of initial treatment response as an indicator of outcomes.
|
Issue 673: August 25, 2017
 Junken Aoki, Pharm.D., Professor of Molecular and Cellular Biochemistry, Tohoku University Graduate School of Pharmaceutical Sciences, on Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6.
|
Issue 671: August 11, 2017
 Ryan Sysko, CEO and Founder, Amalgam Rx, Inc., on delivering better health outcomes with apps.
|
Issue 669: July 28, 2017
 Mark Swindells, Ph.D., Chief Operating Officer, Exscientia, Ltd., on automating drug design.
|
Issue 668: July 21, 2017
  Amy Schulman, Co-Founder and Chief Executive Officer, and Jessica Ballinger, Vice President of Reimbursement and Strategic Alliances, Lyndra, Inc., on moving from daily dosing to weekly dosing and beyond.
|
Issue 667: July 14, 2017
 David Merryman, Ph.D., Associate Professor of Biomedical Engineering, Pharmacology, Medicine, and Pediatrics, and Associate Chair of Biomedical Engineering, Vanderbilt University, on blocking cadherin-11 as a potential treatment for calcific aortic valve disease.
|
Issue 664: June 16, 2017
 Noah Craft, MD, PhD, DTMH, Co-Founder and CEO, Science 37, on bringing clinical trials to the homes of patients.
|
Issue 660: May 19, 2017
 Michael Levin, Ph.D., Professor, Vannevar Bush Chair, and Director, Allen Discovery Center at Tufts University, and Tufts Center for Regenerative and Developmental Biology, on treating atopic dermatitis through autografts of benign bacteria.
|
Issue 657: April 28, 2017
  Robert McNeil, Ph.D., Chief Executive Officer, and Donald M. Black, M.D., Chief Medical Officer, DalCor Pharmaceuticals, on exploring the limits of brain plasticity.
|
Issue 656: April 21, 2017
 Teruaki Nakatsuji, Ph.D., Project Scientist, Department of Dermatology, UC San Diego School of Medicine, on treating atopic dermatitis through autografts of benign bacteria.
|
Issue 655: April 7, 2017
 Milton H. Werner, Ph.D., Founder, President, and CEO, Inhibikase Therapeutics, on developing a disease modifying treatment for Parkinson’s disease.
|
Issue 654: March 31, 2017
 Michael Snyder, Ph.D., Stanford W. Ascherman Professor and Chair, Department of Genetics, and Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, on bringing wearable devices into clinical use.
|
Issue 653: March 24, 2017
 Pierre Beauparlant, Ph.D., Chief Business Officer, Diazon Pharmaceuticals Inc., on developing a potent microtubule-targeting agent with less toxicity.
|
Issue 651: March 10, 2017
 Michael Hooven, President and CEO, Enable Injections, Inc., on improving the way biologics are delivered.
|
Issue 649: February 24, 2017
 Jay Yourist, Ph.D., President & Chief Executive Officer, Nuovo Biologics LLC, on developing treatments for animals, and possibly humans.
|
Issue 648: February 17, 2017
 Tim Errington, Ph.D., Metascience Manager, Center for Open Science, on the difficulties of reproducing research results.
|
Issue 646: February 3, 2017
 Stanley Kim, Co-founder and CEO, WinSanTor, Inc., on restoring sensory fibers in peripheral neuropathy.
|
Issue 644: January 20, 2017
 Keith Murphy, Chairman and Chief Executive Officer, Organovo Holdings, Inc., on engineering human tissues for pharmaceutical screening.
|
Issue 643: January 13, 2017
 Catharina Boehme. M.D., Chief Executive Officer, Foundation for Innovative New Diagnostics, on developing diagnostics for poverty-related diseases.
|
Issue 641: December 23, 2016
 Geoff MacKay, President and CEO, AvroBio, Inc., on quickly bringing novel gene therapies into the clinic.
|
Issue 640: December 16, 2016
  Ted Yednock, Ph.D., Chief Scientific Officer, and Douglas Love, President and CEO, Annexon Biosciences, on targeting the complement pathway in neurodegenerative diseases.
|
Issue 639: December 9, 2016
 Linda Summerton, Ph.D., CEO, Immodulon Therapeutics Ltd., on triggering the immune system to fight cancer with mycobacteria.
|
Issue 638: December 2, 2016
 Aftab Ansari, Ph.D., Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, and Research Professor, Yerkes National Primate Research Center, on opening the potential for sustained control of HIV infection.
|
Issue 637: November 18, 2016
 Jack W. Reich, Ph.D., CEO and Co-founder, Renova Therapeutics, on gene therapy to normalize heart function in heart failure patients.
|
Issue 634: October 28, 2016
 Alex Haahr Gouliaev, Ph.D., Co-founder and Chief Executive Officer, Nuevolution AB, on efficiently identifying small-molecule drug candidates for difficult targets.
|
Issue 632: October 14, 2016
 Sylvain Martel, Ph.D., Professor and Director, NanoRobotics Laboratory, Department of Computer and Software Engineering, Institute of Biomedical Engingeering, Polytechnique, on delivering drugs to the optimal location inside tumors.
|
Issue 631: October 7, 2016
 Sau (Larry) Lee, Ph.D., Deputy Director (Acting), Office of Testing and Research, Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research, FDA, on encouraging industry adoption of continuous manufacturing.
|
Issue 629: September 23, 2016
  Gergely Tóth, Ph.D., M.B.A., Founder and Chief Executive Officer, and Thomas Sawyer, Ph.D., M.B.A., Chief Operations Officer, Cantabio Pharmaceuticals Inc., on pursuing novel treatment strategies for neurodegenerative diseases.
|
Issue 628: September 16, 2016
 Andrew M. Radin, Chief Business Officer & Co-Founder, TwoXAR, on using predictive algorithms to identify novel drug candidates.
|
Issue 627: September 9, 2016
 Jack A. Syage, Ph.D., CEO and Co-founder, ImmunogenX, on developing a treatment and diagnostic tools for celiac disease.
|
Issue 625: August 26, 2016
 Dane M. Chetkovich, M.D., Ph.D., Professor of Neurology and Physiology, Northwestern University Feinberg School of Medicine, on a new potential drug target for the treatment of depression.
|
Issue 623: August 12, 2016
 Christian Tidona, Ph.D., Managing Director, BioMed X Innovation Center, on creating innovative research teams to collaborate with industry.
|
Issue 621: July 29, 2016
 Anthony J. Filiano, Ph.D., Postdoctoral Researcher, Center for Brain Immunology and Glia, School of Medicine, University of Virginia, on uncovering the connections between the immune system, brain circuits, and behavior.
|
Issue 618: July 8, 2016
 Bharatt Chowrira, Ph.D., J.D., President, Synlogic, on developing programmable probiotics as a novel class of therapeutics.
|
Issue 617: June 24, 2016
 Layton Smith, Ph.D., Assistant Professor and Director, Florida Drug Discovery, the Florida Translational Research Program at the Sanford Burnham Prebys Medical Discovery Institute, on advancing the frontiers of academic drug discovery.
|
Issue 616: June 17, 2016
 Charles Swanton, FRCP, Ph.D., Group Leader, the Francis Crick Institute, on understanding tumor evolution to develop better treatment strategies.
|
Issue 612: May 13, 2016
 Jean-François Mouney, CEO and Chairman, GENFIT, on positioning Elafibranor as a first-line treatment in NASH.
|
Issue 610: April 29, 2016
 Joseph S. Beckman, Ph.D., Principal Investigator and Burgess and Elizabeth Jamieson Chair in Healthspan Research, Linus Pauling Institute, Distinguished Professor, Department of Biochemistry and Biophysics, and Director, Environmental Health Sciences Center, Oregon State University, on preclinical breakthroughs in ALS now heading into the clinic.
|
Issue 609: April 22, 2016
 Pablo Graiver, Founder and CEO, TrialReach, on making it easy for patients to connect to clinical trials.
|
Issue 608: April 15, 2016
 Guoping Feng, Ph.D., Investigator, McGovern Institute for Brain Research, and Poitras Professor of Neuroscience, MIT, and Director, Model Systems and Neurobiology, Stanley Center for Psychiatric Research at the Broad Institute, on uncovering the mechanisms underlying autism spectrom disorder.
|
Issue 603: March 11, 2016
 Robert Masella, Partner, Shearman & Sterling, on the outlook for M&A activity.
|
Issue 602: March 4, 2016
 William Flavahan, Ph.D., Postdoctoral Fellow, Massachusetts General Hospital and Harvard Medical School, on new insights into oncogene activation in IDH mutant gliomas.
|
Issue 601: February 26, 2016
 Niven R. Narain, Co-Founder, President & Chief Executive Officer, Berg LLC, on integrating big data to drive drug discovery and development.
|
Issue 600: February 19, 2016
 Apkar Vania Apkarian, Ph.D., Professor of Physiology, Northwestern University Feinberg School of Medicine, on reversing the remodeling of the brain associated with chronic pain.
|
Issue 599: February 12, 2016
 Jon Palfreman, Ph.D., author of Brain Storms, on tracking research developments in Parkinson’s, now as a patient.
|
Issue 595: January 15, 2016
 David Fellows, Chief Executive Officer and Board Member, NightstaRx Ltd., on developing gene therapies for inherited retinal dystrophies.
|
Issue 592: December 11, 2015
 Dallas E. Hughes, Ph.D., President, NovoBiotic Pharmaceuticals, LLC, on developing a platform for discovering new classes of antibiotics.
|
Issue 590: November 20, 2015
 Minoru Takasato, Ph.D., Senior Researcher at the Murdoch Childrens Research Institute, on creating a kidney organoid that contains all human kidney cell types.
|
Issue 589: November 13, 2015
 Joseph S. McCracken, D.V.M., Vice President of Business Development, Alkahest, Inc., on using young plasma to treat Alzheimer’s disease.
|
Issue 588: November 6, 2015
 Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies and Canada Research Chair in Genetics of Pain (Tier I) at McGill University, on the increasing placebo response over time in US clinical trials of neuropathic pain.
|
Issue 585: October 9, 2015
 Margarita Behrens, Ph.D., Staff Scientist, Salk Institute for Biological Studies, on the role of mGluR5 in the development of parvalbumin-positive interneurons and neurodevelopmental disorders.
|
Issue 584: October 2, 2015
 Kang Zhang, M.D., Ph.D., Professor of Ophthalmology and Chief of Ophthalmic Genetics, University of California, San Diego, on reversing cataracts with lanosterol.
|
Issue 583: September 25, 2015
 Thomas West, Project Director and Manager of Intellectual Property, Aprecia Pharmaceuticals Company, on a novel formulation to improve adherence for those with difficulty swallowing pills.
|
Issue 581: September 11, 2015
 Nathalie Donne, Director of Corporate Communication & Business Development, DBV Technologies, on meeting unmet needs in severe food allergies.
|
Issue 579: August 28, 2015
 Greg Duncan, President and Chief Executive Officer, Celtaxsys, Inc., on downregulating the neutrophil response in inflammatory disorders.
|
Issue 578: August 21, 2015
 Alexis C. Wallace, Co-founder, President, and Chief Executive Officer, Thrombolytic Science International, LLC, on extending the treatment window for stroke with greater safety.
|
Issue 576: August 7, 2015
 Tsuyoshi Inoue, PharmD, Associate Professor, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, on developing epilepsy treatment targeting the LDH metabolic enzyme.
|
Issue 574: July 24, 2015
 Luis A. Diaz, Jr., M.D., Associate Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, on mismatch repair deficiency and response to PD-1 inhibitors.
|
Issue 572: July 10, 2015
 Ted J. Kaptchuk, Professor of Medicine, Harvard Medical School, on investigating the genetic components of the placebo effect.
|
Issue 571: June 26, 2015
 Pascale Malgouyres, Pharm D, MSc, Chief Commercial Officer and Co-Founder, Poxel SA, on developing a pipeline of novel treatments for type 2 diabetes.
|
Issue 569: June 12, 2015
 Charles Magness, Ph.D., President and CEO, Kineta, Inc., on building a more efficient model of early-stage drug development.
|
Issue 567: May 29, 2015
 Andrew Vaillant, Ph.D., Chief Scientific Officer, RepliCor, on developing new treatments for Hepatitis B focused on subvirus particles.
|
Issue 566: May 22, 2015
 Konrad Glund, Ph.D., Co-founder and CEO, Probiodrug AG, on moving from research discovery to clinical development in Alzheimer’s disease.
|
Issue 565: May 15, 2015
 Raúl Insa, M.D., Ph.D., Founder & CEO, SOM Biotech SL, on screening existing drugs for new indications.
|
Issue 564: May 8, 2015
 William Moore., Ph.D., President and CEO, Innocrin Pharmaceuticals, Inc., on developing a new class of CYP17 lyase inhibitors.
|
Issue 562: April 24, 2015
 Jos Joore, Ph.D., Co-founder and Chief Business Officer, Mimetas B.V., on building high-throughput organs-on-chips.
|
Issue 560: April 10, 2015
 Rudolph E. Tanzi, Ph.D., Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School, and Director, Genetics and Aging Research Unit, Massachusetts General Hospital, and Doo Yeon Kim, Ph.D., Assistant Professor of Neurology, Harvard Medical School, and Assistant in Neurology, Genetics and Aging Research Unit, Massachusetts General Hospital, on a new and better preclinical model of Alzheimer’s disease.
|
Issue 559: April 2, 2015
 Alexey Terskikh, Ph.D., Associate Professor, Sanford-Burnham Medical Research Institute, on developing a treatment to regrow hair.
|
Issue 557: March 20, 2015
 Ali Tehrani, Ph.D., President & Chief Executive Officer, Zymeworks Inc., on demonstrating success with bispecific antibodies.
|
Issue 556: March 13, 2015
 Todd C. Brady, M.D., Ph.D., President and CEO, Aldeyra Therapeutics, Inc., on an aldehyde trap to treat inflammatory and other diseases.
|
Issue 555: March 6, 2015
 Brian M. Culley, Chief Executive Officer, Mast Therapeutics, Inc., on developing vepoloxamer for sickle cell disease and other indications.
|
Issue 553: February 20, 2015
 Cedric Francois, M.D., Ph.D., Co-founder & Chief Executive Officer, Apellis Pharmaceuticals, Inc., on being in the clinic with complement immunotherapy.
|
Issue 552: February 13, 2015
 Norikazu Eiki, Former Chairman, Bayer Yakuhin, on breaking through the status quo with revolutionary business models.
|
Issue 550: January 30, 2015
 Alexander Green, Ph.D., Assistant Professor, Department of Chemistry & Biochemistry, Arizona State University, on the design and application of toehold switches.
|
Issue 549: January 23, 2015
 Keith Blackwell, M.D., Ph.D., Associate Research Director, Joslin Diabetes Center, Professor, Department of Genetics, Harvard Medical School, and Faculty Member, Harvard Stem Cell Institute, on identifying biomarkers of longevity.
|
Issue 547: January 9, 2015
 Saad A. Naseer, M.D., President and CEO, The Jack and J.T Snow Scientific Research Foundation, on developing a potential treatment for Wolfram syndrome.
|
Issue 544: December, 2014
 Dendy Young, Chairman, Co-Founder and CEO, Perthera, on building an expert system for personalized cancer treatment.
|
Issue 543: December 5, 2014
 Holly Trautman, PharmD, MS, Co-founder, Aventine Consulting, LLC, on getting reimbursement dossiers right.
|
Issue 541: November 14, 2014
 Christoph Lengauer, Ph.D., Chief Scientific Officer, Blueprint Medicines, on building a pipeline of novel kinase inhibitors.
|
Issue 539: October 31, 2014
 Richard A. Bendis, President and CEO, BioHealth Innovation, Inc., on building a more vibrant life sciences cluster in Maryland.
|
Issue 536: October 10, 2014
 Johan Pontin, CEO, Beryllium, on making an impact in drug discovery.
|
Issue 535: October 3, 2014
 Julia P. Gregory, Chief Executive Officer, ContraFect Corporation, on developing novel approaches for treating infectious diseases.
|
Issue 534: September 26, 2014
 Jeffrey Stein, Ph.D., President and CEO, Cidara Therapeutics, Inc., on addressing unmet needs in infectious diseases.
|
Issue 533: September 19, 2014
 R.J. Tesi, M.D., President and CEO, FPRT Bio, on targeting neuroinflammation with a selective TNF inhibitor.
|
Issue 532: September 12, 2014
 Dario C. Altieri, Executive Vice President, The Wistar Institute, Director and Chief Scientific Officer, The Wistar Cancer Center, and Robert and Penny Fox Distinguished Professor of Cancer Biology, on unraveling the role of TRAP-1 in cell metabolism and tumor biology.
|
Issue 530: August, 29, 2014
 Paul J. Lombroso, M.D., Elizabeth Mears and House Jameson Professor in the Child Study Center, Professor of Neurobiology and of Psychiatry, and Director of the Laboratory of Molecular Neurobiology, Yale University School of Medicine, on inhibiting STEP as a potential treatment for Alzheimer’s Disease.
|
Issue 529: August 22, 2014
 Bruce M. Spiegelman, Ph.D., Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Department of Cell Biology, Harvard Medical School, and Professor, Cancer Biology, Dana-Farber Cancer Institute, on prospects for a potential treatment for cancer cachexia by using tumour-derived parathyroid-hormone-related proteins.
|
Issue 528: August 8, 2014
 Eiji Yoshihara, Ph.D., Salk Institute for Biological Studies, on the significance of the institute’s research in the development of recombinant fibroblast growth factor 1 for the effective treatment of Type 2 Diabetes.
|
Issue 525: July 18, 2014
 Jon Meyer, Principal and Co-founder, Life Science Strategy Group, LLC, on launching the new OutsourcePharma Advisory Board, an anonymized social networking site that provides crowd-sourced reviews of the services of CROs for contract research outsourcing professionals at pharmaceutical companies.
|
Issue 524: July 11, 2014
 Allan Bradley, Ph.D., Founder and Chief Technical Officer, Kymab Limited, on his company’s Kymouse transgenic antibody platform, development programs for fully human monoclonal drugs, and partnering strategy.
|
Issue 523: June 27, 2014
 Rahul Aras, Ph.D., President and Chief Executive Officer, Juventas Therapeutics, Inc., on developing a pipeline of therapies focused on the treatment of heart failure, and his company’s lead development program and partnering strategy.
|
Issue 521: June 13, 2014
 Steve Orndorff, Ph.D., President and CEO, MicroBiome Therapuetics, LLC, on his company’s clinical development programs and approach to developing prebiotics to alter the microbiome in the treatment of a variety of diseases.
|
Issue 519: May 30, 2014
 Jennifer Doudna, Ph.D., Professor, Molecular and Cell Biology Department and Chemistry Department, University of California, Berkeley, Investigator, Howard Hughes Medical Institute, and Faculty Scientist, Lawrence Berkeley National Laboratory, on current research and potential future applications of the CRISPR-Cas system.
|
Issue 518: May 23, 2014
 Jianghong Rao, Ph.D., Associate Professor of Radiology, School of Medicine, Stanford University, on using a nanoparticle that can detect reactive oxygen species and reactive nitrogen species in vivo that could lead to improved methods for liver toxicity testing of drugs.
|
Issue 517: May 16, 2014
 Shivaani Kummar, M.D., Head, Developmental Therapeutics Clinic, National Cancer Institute, on the clinical trial Molecular Profiling based Assignment of Cancer Therapeutics (M-PACT), which determines whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic sold tumors.
|
Issue 513: April 17, 2014
 Mark Kessel, Co-founder, Symphony Capital, on employing a new structure for financing drug development.
|
Issue 512: April 11, 2014
 Adam Gazzaley, M.D., Ph.D., Associate Professor of Neurology, UCSF School of Medicine, on developing a video game to assess and improve cognitive performance.
|
Issue 510: March 28, 2014
 Lyndon Lien, Ph.D., President and CEO of Balance Therapeutics, Inc., on reducing inhibitory signaling as an approach to improving cognitive performance in Down syndrome.
|
Issue 508: March 14, 2014
 John O’Rourke, Vice President of Marketing, Decisyon, Inc., on bringing together people and data to make and execute decisions.
|
Issue 507: March 7, 2014
 Craig M. Crews, Ph.D., Founder and Chief Scientific Advisor of Arvinas, Inc., and Professor, Yale University, using novel platforms to develop small molecules that can induce the degradation of disease-causing proteins.
|
Issue 505: February 21, 2014
 Warren Hosseinion, M.D., CEO of Apollo Medical Holdings, Inc., partnering to improve patient care in COPD.
|
Issue 502: January 31, 2014
Michael Conn, Ph.D., Senior Vice President for Research, Associate Provost and Professor of Internal Medicine and Cell Biology, Texas Tech University Health Sciences Center, on using pharmacoperones to fix misfolded proteins.
|
Issue 501: January 24, 2014
 Yukinori Okada M.D., Ph.D., tenure-track lecturer at Tokyo Medical and Dental University, Department of Human Genetics and Disease Diversity, on seeking new possibilities of genome drug development.
|
Issue 500: January 17, 2014
 Warner C. Greene, M.D., Ph.D., Director, Gladstone Institute of Virology and Immunology, on finding a new potential pathway for HIV treatment.
|
Issue 498: December 20, 2013
 Magali Haas, M.D., Ph.D., M.S.E., Founder and CEO of Orion Bionetworks, on using big data for disease modeling in multiple sclerosis.
|
Issue 495: November 22, 2013
 Edwin Moses, Ph. D., Chairman and CEO of Ablynx, on developing novel proteins based on single-domain antibodies.
|
Issue 494: November 15, 2013
 Laura Shawver, Ph.D., CEO of Cleave Biosciences, on discovering and developing small molecules for targets in protein degradation pathways for cancer treatment.
|
Issue 491: October 25, 2013
 Sakhrat Khizroev, Ph.D., Professor and Vice Chair, Department of Immunology, College of Medicine, and Director, Center for Personalized Nanomedicine, Florida International University, on opening new horizons in medicine with magneto-electric nanoparticles.
|
Issue 489: October 11, 2013
 Dan Paterson, Chief Business Officer and Brian Sullivan, Corporate Development Director, Verastem, Inc., on selectively targeting cancer stem cells.
|
Issue 486: September 20, 2013
 Nancy Simonian, M.D., CEO of Syros Pharmaceuticals, on using super-enhancers to identify the genes driving disease and then developing drugs that inhibit or disrupt those targets.
|
Issue 485: September 13, 2013
 Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center, on opening new horizons for cancer immunotherapy.
|
Issue 483: August 30, 2013
 Derek A. Small, President and CEO and Joseph R. Moskal, Founder and Chief Scientific Officer of Nuarex Inc., on modulating the NMDA receptor for treatment of depression and other CSN disorders.
|
Issue 482: August 23, 2013
 Malcom Weir, Ph.D., Co-founder and CEO of Heptares Therapeutics, on targeting G protein-coupled receptors for Alzheimer’s Disease.
|
Issue 481: August 9, 2013
 Masashi Yanagisawa, M.D., Ph.D.,
Professor of University of Texas Southwestern Medical School and Tsukuba University, on developing orexin receptor agonist in the field of medicinal chemistry.
|
Issue 479: July 26, 2013
 Alain D. Baron, M.D., President and CEO, Elcelyx Therapeutics, on how their delayed release formulation of metformin, works.
|
Issue 477: July 12, 2013
 Jae Chung, Founder and CEO, goBalto Inc., on goBalto’s Tracker 2.0 cloud-based solution and the clinical study startup process.
|
Issue 472: May 31, 2013
 Paul L. Hallenbeck, Ph.D., President and CEO, Synbody Biotechnology Inc., on the company’s synbody platform and partnering strategy.
|
Issue 470: May 17, 2013
 John Holland, Senior Vice President, Business Development and Research, AMC Health, on using remote monitoring in clinical trials and how the FDA is viewing such innovations in trial design.
|
Issue 469: May 10, 2013
 Sapan Shah, Ph.D. President and Chief Executive Officer, ARMGO Pharma Inc., on the target mechanism in the company’s pipeline of novel compounds that utilize a defect in intracellular calcium regulation, and also on the company’s partnering strategy.
|
Issue 467: April 26, 2013
 Pamela Tenaerts, MD, MBA, Executive Director, The Clinical Trials Transformation Initiative (CTTI), on the company’s activities in identifying practices that will increase the quality and efficiency of clinical trials.
|
Issue 466: April 19, 2013
 Nathan Caffo, President, Presage Biosciences, on the company’s proprietary drug array platform for simultaneously analyzing multiple cancer drug candidates within a single living tumor, and how pharmaceutical companies can use it to screen candidate compounds.
|
Issue 464: April 5, 2013
 John A. Latham, Ph.D., Chief Scientific Officer, and Mark J. Litton, Ph.D., MBA, Chief Business Officer and Treasurer, Alder Biopharmaceuticals, Inc, on the company’s development strategy for novel antibody therapeutics as a treatment for migraines.
|
Issue 463: March 28, 2013
 Sanae Shoji, Ph.D, Former Research Associate at University of Texas Southwestern Medical Center, on her pioneering publication, “Identification of a candidate therapeutic autophagy-inducing peptide.”
|
Issue 461: March 15, 2013
 James J. Collins, Ph.D., Co-founder, and Jeffrey D. Wager, M.D., Chairman, President and CEO, EnBiotix, Inc., on the company’s technology and partnering strategy for its novel anti-bacterial platforms.
|
Issue 459: March 1, 2013
 Destry Sulkes, M.D., Executive Vice President and Co-founder, Medivo Inc,. on the company’s services and how pharmaceutical companies can use them to deliver targeted communications to patients and doctors.
|
Issue 458: February 22, 2013
 Garret A. FitzGerald, M.D., Chair, Department of Pharmacology, and Director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, on his group’s research on molecular clocks in the regulation of biologic systems.
|
Issue 457: February 15, 2013
Jonathan Kil, M.D., Chief Medical Officer and Director, Sound Pharmaceuticals, Inc., on SPI’s development programs aiming to prevent and reverse hearing loss.
|
Issue 455: February 1, 2013
Thomas Kassberg, Chief Business Officer and Senior Vice President, Ultragenyx Pharmaceutical, on the company’s pipeline and strategy for developing treatments for rare and ultra-rare metabolic genetic disorders.
|
Issue 452: January 11, 2013
 Swati S. More, Ph.D, Research Associate, Center for Drug Design, University of Minnesota, on her findings from a study together with Professor Robert Vince, Ph.D., in which they found that a synthetic cofactor of glyoxalase was able to prevent neurodegeneration in a mouse model of Alzheimer’s disease.
|
Issue 450: December 21, 2012
 René Bernards, Ph.D., Division Head, Molecular Carcinogenesis, The Netherlands Cancer Institute, on his research findings for a pathway that appears to confer resistance to a variety of cancer drugs.
|
Issue 448: December 7, 2012
Christopher A. Kroeger, M.D., President and CEO, Cardioxyl Pharmaceuticals, Inc, on the advantages of nitroxyl donors and the company’s development programs.
|
Issue 446: November 16, 2012
 Michael Jirousek, Ph.D., Co-founder and Chief Scientific Officer, Catabasis Pharmaceuticals, on the company’s lead program in developing a pipeline focused on the treatment of inflammatory and metabolic diseases by employing its proprietary “linker” technology.
|
Issue 445 November 9, 2012
 D. Lynn Kirkpatrick, Ph.D., President and CEO, Ensysce Biosciences Inc., on the company’s technology and development programs for using single walled carbon nanotubes to deliver short interfering RNA (siRNA) for therapeutic applications in oncology.
|
Issue 443: October 26, 2012
 Elizabeth Iorns Ph.D., Co-Founder & CEO, Science Exchange, on the concept behind and goals for the company’s Reproducibility Initiative, a program designed to help scientists validate studies for publication or commercialization.
|
Issue 442: October 19, 2012
 Julian Bertschinger, Ph.D., Co-founder and Chief Executive Officer, Covagen AG, on the company’s technology platform for creatibng next-generation protein drugs, known as Fynomers, and its partnering strategy.
|
Issue 439: September 21, 2012
 Christopher Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation, on the company’s newly-acquired library of homing peptides and the company’s development programs.
|
Issue 438: September 14, 2012
 Joseph F. Clark, Ph.D., Professor of Neurology, University of Cincinnati, on about his research findings in cyclocreatine as a treatment for creatine transporter deficiency, and the pathway ahead for clinical development of a treatment for the disease.
|
Issue 436: August 31, 2012
 David Kaplan, Ph.D., Stern Family Professor of Engineering, Professor and Chair, Department of Biomedical Engineering, Tufts University, on his research into the properties of silk and its biomedical applications.
|
Issue 434: August 17, 2012
 Fumihiko Urano, M.D., Ph.D., Associate Professor, School of Medicine, Washington University, on his research into how thioredoxin-interacting protein (TXIP) molecules are linked to both ER stress and the production of IL-1β cytokine proteins within beta cells.
|
Issue 431: July 27, 2012
 Werner Lanthaler, Ph.D., Chief Executive Officer, Evotec AG, on the company’s strengths in drug discovery and approach to partnering.
|
Issue 430: July 20, 2012
 Michael Clayman, MD, Chief Executive Officer and Co-founder, Flexion Therapeutics, on the company’s strategic focus, the status of its development programs, and its partnering strategy.
|
Issue 427: June 29, 2012
 Berislav V. Zlokovic, M.D., Ph.D., Professor and Chair, Department of Physiology & Biophysics, and Director, Center for Neurodegeneration & Regeneration, Zilkha Neurogenetic Institute, Keck School of Medicine of USC on his research into the role of APOE4 in breakdowns in the blood-brain barrier.
|
Issue 424: June 1, 2012
 Rangaramanujam M. Kannan, Ph.D., Professor of Ophthalmology, Center for Nanomedicine/Wilmer Eye Institute, Johns Hopkins University School of Medicine, on results from his study on dendrimers for targeted treatment of neuroinflammation.
|
Issue 423: May 25, 2012
 Mark Bard, Co-Founder and Director, the Digital Health Coalition, on how pharmaceutical companies are using social media.
|
Issue 422: May 18. 2012
 Nicholas P. Tatonetti, Ph.D. Candidate in Biomedical Informatics, Stanford University, on his research into an approach for controlling bias when performing data mining on an observational dataset of drug adverse events.
|
Issue 421: May 11, 2012
 Anthony Goldbloom, Founder and CEO, Kaggle Inc., on the company’s business model and how it helps companies and institutions find new ways of analyzing data.
|
Issue 417: April 13, 2012
 Christian Zahnd, Ph.D., CEO, and Patrick Amstutz, Ph.D., Chief Business Officer, Molecular Partners AG, on the company’s pipeline for developing a novel class of protein therapeutics called DARPins, and its partnering strategy.
|
Issue 416: April 5, 2012
 Guido Lanza, President and CEO, Numerate, Inc., on the company’s approach to its in silico drug design, and its partnering model.
|
Issue 415: March 30, 2012
 Professor Akira Sawa, Director, Silvio O. Conte Neuroscience Research Center, Johns Hopkins Schizophrenia Center, on the center’s research into onset mechanisms for schizophrenia, focusing on both environmental and hereditary factors.
|
Issue 411: March 2, 2012
 Mason Tenaglia, Founder and Managing Director, The Amundsen Group, on the benefits of copay support programs for patients and manufacturers, and efforts to restrict the use of such programs.
|
Issue 410: February 24, 2012
 Paul M. Gilbert, Co-Founder and CEO, and Michael J. Detke, MD, PhD, Chief Medical Officer, MedAvante, Inc., on the company’s approach to bringing greater standardization to patient assessments in CNS clinical trials through the use of centralized raters, and its activities.
|
Issue 409: February 17, 2012
 George G. Montgomery, Managing Director, Sagent Advisors, on M&A trends in the biopharma sector.
|
Issue 401: December 16, 2011
 Hisataka Kobayashi, M.D., Ph.D., National Cancer Institute, Molecular Imaging Program, on research into photoimmunotherapy, and its future outlook as a new treatment for cancer.
|
Issue 400: December 9, 2011
 Bertrand C. Liang, M.D., Ph.D., M.B.A., Chief Executive Officer, Pfenex Inc., on the company’s unique protein expression platform that utilizes the microorganism Pseudomonas fluorescens in a high-throughput process for rapidly identifying high-quality protein production strains, and its partnering strategy.
|
Issue 398: November 18, 2011
 Brian Overstreet, Co-founder and President, AdverseEvents, Inc., on the company’s database of adverse drug events reported the FDA, and its buisness model.
|
Issue 397: November 11, 2011
 Marcus Wilson, Pharm.D., President and Co-Founder of the HealthCore Unit of WellPoint, Inc., on the company’s major collaboration with AstraZeneca, and its activities.
|
Issue 395: October 28, 2011
 Daniel Conners, Chairman and President, Biothera Pharmaceutical Group, on the company’s development programs and partnering strategy.
|
Issue 394: October 21, 2011
 P. Ron Ellis, Co-Founder, President, and CEO, Endocyte, Inc., on the company’s technology platform for a pipeline of small molecule drug conjugates for treating cancer as well as inflammatory diseases, its development programs, and its partnering strategy.
|
Issue 393: October 14, 2011
 Richard A. Basile, CEO, BioPontis Alliance, LLC, on the company’s model and plans.
|
Issue 392: October 7, 2011
 David H. Kirn, M.D., Founder, President and CEO, Jennerex Biotherapeutics, Inc., on targeted oncolytic virus products for cancer, and the company’s lead compound, JX-594.
|
Issue 391: September 30, 2011
 Mark Pruzanski, M.D., Founder, President and CEO, Intercept Pharmaceuticals, Inc., on the company’s focus and partnering strategy.
|
Issue 390: September 23, 2011
 Atul Butte, M.D., Ph.D., Division Chief and Associate Professor in Pediatrics (Systems Medicine), Medicine and Pediatrics, Stanford University School of Medicine, on his research into how expression data could be used to find new indications for existing drugs, and a new company he has founded for commercial applications of the technology.
|
Issue 389: September 16, 2011
 Ramy Farid, Ph.D., President, and Shi-Yi Liu, Ph.D., Senior Vice President for Marketing, Schrödinger, LLC, on the company’s activities and its subsidiary in Japan.
|
Issue 387: August 26, 2011
 Shinichi Takeda M.D., Ph.D., Director, Translational Medical Center, National Center of Neurology and Psychology, on both the therapeutic potential of exon-skipping therapy for Duchenne muscular dystrophy and its continued doctoral research.
|
Issue 386: August 12, 2011
 Anthony McKinney, President, CEO and Co-Founder, Euthymics Bioscience, on the company’s development programs for novel medicines for major depressive disorder and ADHD, and its partnering strategy.
|
Issue 385: August 5, 2011
Gordon H. Busenbark, Senior Vice President and Chief Financial Officer, Inspiration Biopharmaceuticals, Inc. on the company’s development programs for a pipeline of treatments for hemophilia, and the structure of its partnership with Ipse.
|
Issue 383: July 22, 2011
 Anthony Costello, Chief Operating Officer, Mytrus, Inc. on the company’s approach for enabling patients to participate in clinical trials from the convenience of their own homes, and the benefits for patients and pharmaceutical companies.
|
Issue 382: July 15, 2011
 Philip E. Bourne, Ph.D., Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego on his findings and research approach to modeling the effects of a drug’s interactions with multiple receptors.
|
Issue 381: July 8, 2011
 Chip Clark, President and Chief Executive Officer, Genocea Biosciences, on the company’s vaccine technology platform, pipeline, and its partnering strategy.
|
Issue 380: July 1, 2011
 William J. Newell, CEO, Sutro Biopharma, Inc., on the company’s biochemical protein synthesis technology platform and its partnering strategy.
|
Issue 379: June 24, 2011
 Toru Hosoda, M.D., Ph.D., Associate Professor, Department of Medicine, National Institute of Science and Technology, Tokai University, on the first successful identification of stem cells from a human lung.
|
Issue 378: June 17, 2011
 Katherine S. Bowdish, Ph.D., Chief Executive Officer, Anaphore, Inc. on the company’s Atrimer platform, in-house development initiatives, and its partnering strategy.
|
Issue 376: June 3, 2011
 Shinichi Yachida, M.D., Ph.D., Research Associate, Department of Gastrointestinal Surgery, Kagawa University Hospital, on clarifying the genetic evolution and metastatic mechanisms of pancreatic cancer through genome analysis.
|
Issue 375: May 27, 2011
 Alan S. Klein, Executive Vice President, Corporate Development, Sequella Inc., on the company’s new antibiotic mechanism for treating TB and helicobacter pylori.
|
Issue 374: May 20, 2011
 Derek Chalmers, Ph.D., President and CEO, Cara Therapeutics, Inc., on the company’s development of a new analgesic without CNS Side Effects.
|
Issue 370: April 21, 2011
 Scott Johnson, President and Founder, Myelin Repair Foundation, on how the company is pioneering a new model for drug discovery and developing a new approach to treating multiple sclerosis.
|
Issue 369: April 15, 2011
 Dr. Krisztina Zsebo,
President and CEO, Celladon Corporation, on a genetically-targeted enzyme replacement therapy for treating heart failure.
|
B. Frank Gupton, Ph.D., Chief Executive Officer, Medicines for All Institute at Virginia Commonwealth University, on eliminating waste and inefficiency in the drug manufacturing process.
Kelly Cobey, Ph.D., Scientist at the University of Ottawa Heart Institute, on the problems surrounding reproducibility in the field of biomedical research.
Jay Short, Ph.D., Chairman, CEO, and Co-founder of BioAtla, on selectively targeting tumor cells to treat patient populations with high unmet need.
David J. Earp, J.D., Ph.D., President and CEO of Circle Pharma, on developing a new generation of macrocycle therapies to treat historically undruggable targets.
Nikole Kimes, Ph.D., Co-Founder and Chief Executive Officer of Siolta Therapeutics, on pioneering a preventative approach to diseases stemming from the gut microbiome.
Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, on leveraging machine learning and AI-enabled maps of biology to further advance drug discovery and development.
Marcio Souza, President and CEO of Praxis Precision Medicines, on creating a novel treatment to address an unmet medical need in patients with DEE.
Kenneth Getz, Executive Director and Research Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine, on bringing together industry insights through a pre-competitive DCT consortium.
Louis Reese, Co-founder and Executive Chairman of Vaxxinity, on leveraging an innovative platform to deliver immunotherapeutic vaccines for chronic diseases.
Dr. Catherine Pearce, CEO and Co-founder of JucaBio, on bringing innovative new drugs with flexible, small organizational units.
Brian Feldman, M.D., Ph.D., Walter L. Miller Distinguished Professor at the University of California, San Francisco, Department of Pediatrics, Devision of Pediatric Endocrinology, on finding the mechanism for converting white adipocytes to beige adipocytes.
Pablo Penaloza-MacMaster, Ph.D., Associate Professor of Microbiology-Immunology, Northwestern University, on discovering the antitumoral effects of r3LCMV.
Benjamin Ineichen, M.D., Ph.D., Junior Group Leader at the Center for Reproducible Science at the University of Zurich, on how to improve the translational success rate of therapeutical development from animal to human studies.
David Gutmann, M.D., Ph.D., Professor at Washington University of Medicine in St. Louis, on the groundbreaking discovery of a novel treatment for preventing the formation of tumors stemming from NF1.
Ken Horne, Managing Partner at AN Venture Partners, on investing in Japan bioscience, but going global from day one.
Eli Wallace, Ph.D., CEO of BridgeBio Oncology Therapeutics, on paving the way in next-generation oncological therapeutics.
Seema Nandi, Ph.D., Co-Founder and CEO at SelSym Biotech, on developing innovative synthetic platelets to address clinical needs in bleeding management and improve patient outcomes.
Justin Ichida, Ph.D., Associate Professor in the Department of Stem Cell Biology and Regenerative Medicine, University of Southern California, on making a novel discovery that could pave the way for future TBI treatments.
Harsha K. Rajasimha, M.S., Ph.D., Founder and CEO of Jeeva Clinical Trials, on bringing clinical trials into the modern era and leveraging an all-in-one platform to make clinical trials more efficient and accessible.
Mark Kreston and Calman Prussin, M.D., Chief Commercial Officer and Chief Scientific Officer of Areteia Therapeutics, on developing an innovative therapy to better the lives of asthma patients.
Jonathan Kipnis, Ph.D., Edith L. Wolff Distinguished Professor of Neurology, Neuroscience and Neurosurgery, and Director of the Brain Immunology and Glia Center at the Washington University School of Medicine in St. Louis, on making the groundbreaking discovery of a direct connection between the brain and dura matter.
Stephen Badylak, Ph.D., M.D., Co-Founder, Chief Science Officer, ECM Therapeutics, on utilizing novel versions of ECM to address unmet medical needs.
Matt Kane, CEO and Director at Tune Therapeutics, on pioneering the next generation of epigenome editing.
Roger Hajjar, M.D., Director of MGB Gene and Cell Therapy Institute at Mass General Brigham, on streamlining the discovery and trials of innovative treatments.
Dr. Michael Crackower, Ph.D, Founder and Chief Scientific Officer at BrainChild Bio, Inc., on revolutionizing CAR T-cell therapy in CNS cancers.
Dr. Michael Jensen, M.D., Research Professor in the Center for Genetic Epidemiology, Department of Population and Public Health Sciences at Keck School of Medicine, University of Southern California, on her groundbreaking research on hyperemesis gravidarum and discovering the cause of the disease and identifying potential treatments.
Dr. Michael Crackower, Ph.D, Chief Scientific Officer at Ventus Therapeutics, on leveraging structural biology and computational chemistry tools to pioneer novel medicines.
Andrew Allen, M.D., Ph.D., Co-founder, President and CEO of Gritstone bio, on leading the way in developing next-generation vaccines.
Peter M. Tessier, Ph.D., Albert M. Mattocks Professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, on paving the way for the use of machine learning to optimize therapeutic antibodies.
Hamideh Parhiz, Pharm.D., Ph.D., Research Assistant Professor in the Division of Infectious Diseases at the Perelman School of Medicine at the University of Pennsylvania, on pioneering the frontier of targeted mRNA-based in vivo gene therapy.
Steve Uden, M.D. and Martin Mackay, Ph.D., Co-Founder and Chief Executive Officer of Rallybio and Co-Founder and Executive Chairman of Rallybio, on developing and delivering transformative therapies.
Gregg Silverman, M.D., Professor of Medicine and Pathology at NYU School of Medicine, on discovering the link between lupus and the gut microbiome.
Joseph Kim, Chief Strategy Officer of ProofPilot, on pioneering the digital automation of antibodies.
Matt Maisak, Ph.D., CEO of Covant Therapeutics, on leading the way in developing novel therapies.
John K. Celebi, President and CEO of Sensei Biotherapeutics, Inc., on pioneering the frontier of VISTA-inhibiting antibodies.
Rodney Varner, Co-founder, Chairman, and CEO of Genprex, Inc., on leveraging two novel gene therapies for cancer and diabetes.
Kenichiro Kuninobu, Ph.D., Co-Founder and CEO of Feliqs, on developing a new drug targeting ferroptosis.
Dan Passeri, M.Sc., J.D., CEO of Cue Biopharma, on developing the future of IL-2 therapies.
Tony Reid, M.D., Ph.D., CEO of EpicentRx Inc., on developing a very safe drug with multifaceted benefits.
Peter J. Chockley, PH.D, postdoctoral researcher at St. Jude Children’s Research Hospital, on optimizing the design of CARs with an anchoring protein.
David K. Barr, Esq., Partner at Stroock & Stroock & Lavan LLP, on intellectual property complexities in cell and gene therapies.
Chris Wasden, Ph.D., Ameet Nathwani, M.D., CEO of Dewpoint, on pioneering the frontier of condensate biology.
Chris Wasden, Ph.D., Chief Strategy Officer of Twill, on creating integrated care with digital therapeutics.
Scott Minick, President and CEO, BIND Biosciences, on the company’s therapeutic targeted nanoparticle technology.
Robert Shore, M.D., CEO, and Timothy Sullivan, Executive Vice President,
Robert L. Kirkman, M.D., President and CEO, and Scott Peterson, Ph.D., Vice President of Research and Development, Oncothyreon, on the company’s PI3K inhibitor.
Ernest Wong, Ph.D., M.B.A., Vice President, YM Biosciences, about the company’s JAK inhibitor program in myelofibrosis.
Masayuki Yazawa, Ph.D., Postdoctoral Research Fellow, Stanford University, on the use of iPS cells to treat Timothy Syndrome.
William S. Marshall, Ph.D. President and CEO of miRagen Therapeutics, about the company’s miRNA-targeted drugs.
Arthur Sands, M.D., Ph.D., President and CEO, Lexicon Pharmaceuticals, about the company’s development programs and partnering strategy.
Katrine Bosley, CEO of Avila Therapeutics, about the company’s discovery platform for targeted covalent drugs.
Robert Kneller, J.D., M.D., M.P.H., Professor, Research Center for Advanced Science and Technology (RCAST), University of Tokyo, on the differences between pharma and academia in drug discovery innovation.
Aris Persidis, PhD., President and Co-Founder, Biovista Inc., on using mechanism of action to predict safety and efficacy.
Thomas Hughes, Ph.D., President and CEO of Zafgen Inc., on the company’s lead candidate compound that promotes sustained weight loss through MetAP2 inhibition
Eggehard Holler, Ph.D., University of Regensburg, Julia Ljubimova, M.D., Ph.D., Cedars-Sinai Medical Center, and Maurizio Vecchione, CEO, Arrogene Nanotechnology, on a nanoconjugate technology for treating brain …
John E. Wennberg, M.D., M.P.H., Peggy Y. Thomson Professor in the Evaluative Clinical Sciences, Dartmouth Medical School, on a rational approach to supply and demand in medicine.
Tillman U. Gerngross, Ph.D., CEO of Adimab Inc., on the company’s novel antibody discovery platform.
Kobi M. Sethna, President and CEO, Nereus Pharmaceuticals, on leveraging marine microbes as a source of novel pharmaceutical agents.
Richard L. Atkinson, M.D., Clinical Professor of Pathology, Virginia Commonwealth University, and President, Obetech, LLC, on the evidence for a causal link between AD36 and obesity.
Kathleen Sereda Glaub, President, Plexxikon, on the company’s lead drug candidate for melanoma.
Harald Fricke, M.D., Ph.D., CMO and COO, Apogenix, on an innovative therapeutic approach to treating glioblastoma.
Stephen Engle, Chairman and CEO, XOMA, on developing a therapeutic antibody-based approach to diabetes treatment.
Soichi Matsuno, Advisor, Eisai Co., Ltd., on how the company’s pioneering spirit has contributed to its global expansion.
Maria L. Maccecchini, Ph.D., President & CEO, QR Pharma, on an approach to inhibiting amyloid formation in targeting mild cognitive impairment and Alzheimer’s disease.
Marc Cantillon, M.D., Director of the Coalition Against Major Diseases at the Critical Path Institute, on accelerating Alzheimer’s drug development through data collaboration.
Gordon McCauley, President and CEO, Allon Therapeutics Inc., on targeting neurodegenerative diseases with activity-dependent neuroprotective protein.
Robert Gould, Ph.D., President and CEO, and Jason Rhodes, EVP and Chief Business Officer of Epizyme, on transforming cancer therapy via HMT inhibition.
Tom Smart, Chairman and CEO, AnaptysBio, on leveraging a novel platform for antibody generation.
Roger H. Unger, M.D., Professor of Internal Medicine, University of Texas South Western Medical Center, on the comparison of leptin and insulin levels in mouse models of type 1 diabetes.
Adam Bosworth, Founder and CTO of Keas, on using intelligent computing to improve patient outcomes.
Christopher S. Meldrum, President, Pique Therapeutics, on non-immunogenic cancer treatment using allogenic vaccine therapies.
Andrew M. Thompson, Co-Founder and CEO, Proteus Biomedical, on the company’s advancements in intelligent medicine.
Stephen H. Friend, M.D., Ph.D., President, CEO and Co-Founder, Sage Bionetworks, on the development of a shared data repository of clinical data to improve disease modeling.
Alpheus Bingham, Ph.D., Founder and Director, InnoCentive Inc., on an incentive-based open innovation model for helping organizations solve research problems.
Per Olof Wallström, President and CEO, and Erika Söderberg Johnson, CFO, Karo Bio, on the development of innovative therapeutics targeting nuclear receptors.
Joshua Kazam, President and CEO, Nile Therapeutics, on the company’s application of natriuretic peptides to treat heart failure.
Kees Been, President and CEO, EnVivo Pharmaceuticals, on enhancing cognitive function in Alzheimer’s disease and schizophrenia patients.
Benjamin Heywood, Co-Founder and President, PatientsLikeMe, on the company’s platform for connecting patients and pharma through social networking.
Randall L. Carpenter, M.D., Co-Founder, President and CEO, Seaside Therapeutics, on the development of novel therapies for Fragile X Syndrome.
Joseph P. Pieroni, CEO, Daiichi Sankyo Inc., on the company’s marketing strategy for Effient.
Judy Mikovits, Ph.D, Director of Research at the Whittemore Peterson Institute, on the correlation between XMRV and Chronic Fatigue Syndrome.
David Rose, CEO, Vitality, on GlowCaps, the company’s breakthrough technology to promote medicine adherence.
Jennifer A. Low, MD, PhD, Global Clinical Lead for GTC-0449, Genentech, on Promising Early Clinical Results for a Hedgehog Inhibitor in Cancer.
Julia P. Gregory, President and CEO, Five Prime Therapeutics, Inc., on the company’s unique discovery platform.
Shingo Kajimura, Ph. D., Instructor in Cell Biology, Dana-Farber Cancer Institute, on the transcription mechanism of brown fat formation from myoblastic precursors.
Robert H. Uhl, Senior Director of Investor Relations, Halozyme Therapeutics, on the company’s recombinant human hyaluronidase-based drug delivery platform.
Dr. Gail Naughton, CEO, Histogen, Inc., on the use of embryonic protein WNT7A to counteract hair loss.
Neil Warma, President and CEO of Opexa Therapeutics, on an individually tailored cell therapy for multiple sclerosis.
Vijay B. Samant, President and CEO, Vical, Inc., on the potential applications of its DNA-based vaccine delivery technology.
Robert Gatenby, M.D., Chairman of the Departments of Diagnostic Imaging and Integrative Mathematical Oncology, H. Lee Moffitt Cancer Center, on the adaptive therapy approach to cancer treatment.
Vince Kuraitis, Principal and Founder, Better Health Technologies, LLC, on the future of the disease management industry.
Gregory Perry, Senior Vice President and CFO, ImmunoGen, Inc., on the role of ImmunoGen’s Targeted Antibody Payload (TAP) technology in developing better tolerated anticancer drugs.
Saeid Akhtari, Co-Founder, President and CEO, NextBio, on the company’s bioinformation search platform.
Shawn Lyndon, Founder, President and CEO, Orasi Medical, on the use of magnetoencephalography (MEG) to diagnose neurological diseases.
Eric Elliott, President, CIGNA Pharmacy Management, on CIGNA’s recent performance-based contract with Merck.
Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition, on the status of personalized medicine in the United States.
Bruce S. Auerbach, M.D., FACEP, President, Massachusetts Medical Society, on the implications of Massachusetts’ shortage of primary care physicians.
Yoshimi Kuroiwa, Ph.D., Executive Research Director, Hematech, Inc. on the production of polyclonal antibodies using genetically modified cattle.
Vincent Mutel, Ph.D., Co-Founder, Vice Chairman and CEO, Addex Pharmaceuticals, on the advantages of allosteric modulators for G-protein coupled receptors (GPCRs).
Jason Hwang, M.D., Executive Director of Healthcare, Innosight Institute, on the forces shaping change in the pharmaceutical industry as articulated in his book, The Innovator’s Prescription.
Scott Weir, PharmD, Ph.D., Professor and Director of the Office of Therapeutics, Discovery and Development for the University of Kansas Medical Center, on his group’s drug development partnership with the Leukemia & Lymphoma Society (LLS).
Mollie Shields-Uehling, President & CEO, SAFE-BioPharma Association, on creating a digital signature standard for the pharmaceutical industry.
Les Jordan, Life Sciences Industry Technology Strategist, Microsoft Corporation, on bringing order to the cacophony of data.
Thomas Neyarapally, Vice President, Corporate Strategy and Intellectual Property, Gene Network Sciences, on interrogating data to identify novel drug targets and drug effects.
Robert S. Becker, Ph.D., MBA, Vice President, Business Development, VaxInnate Corporation, on developing a potent universal flu vaccine.
James J. O’Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc., on moving into phase 3 with a novel treatment for gastrointestinal disorders..
Hironori Hozoji, Investment Officer, JAFCO Life Science Investment, on cultivating portfolio companies with better exit possibilities.
David Steinberg, CEO, Enlight Biosciences, and Senior Principal, Puretech Ventures, on developing technologies for pharma R&D.
Danong Chen, Ph.D., President and CEO, Theranostics Health, on protein profiling and targeted therapies.
Javier Gonzalez-Maeso, Ph.D., Assistant Professor, Departments of Neurology and Psychiatry, Mount Sinai School of Medicine, on new perspectives on the molecular mechanisms of schizophrenia.
Ellen Coleman, Executive Vice President, Emerging Med, on matching patients with clinical trials for cancer treatments.
Nicholas J. Seay, Chief Technology Officer, Cellular Dynamics International, on the next stage in cell-based drug toxicity screening.
Jacqueline A. French, MD, Professor of Neurology, New York University School of Medicine, on treatment choice and development challenges for anti-epileptic drugs.
Howard Martin Fillit, M.D., Executive Director, Alzheimer’s Drug Discovery Foundation, on the role of venture philanthropy in accelerating drug discovery for Alzheimer’s disease.
Jayakrishna Ambati, M.D., Professor of Physiology and Professor & Vice-Chair of Ophthalmology and Visual Sciences, University of Kentucky, on the mechanism of siRNA treatments in clinical development for macular degeneration.
Keizo Koya, Ph.D., Senior Vice President, Drug Development, Synta Pharmaceuticals Corp., on killing cancer cells through oxidative stress.
Anthony J. Varano, Jr., Founder, President and CEO, DSG Inc., on opening doors to clinical trial efficiencies and savings with EDC software.
David G. Stevenson, S.M., Ph.D., Assistant Professor, Department of Health Care Policy, Harvard Medical School, on the special challenges posed by Part D for nursing home residents.
Joe Dougherty, Ph.D., Co-Founder and Partner, Seaview Securities LLC, on LigoCyte and prospects in the financing market for biotech ventures.
Adam J. Fein, Ph.D., Founder and President, Pembroke Consulting, Inc., on the interface between PBMs and retail pharmacies.
Bernhardt L. Trout, Professor, Department of Chemical Engineering, Massachusetts Institute of Technology, on optimizing drug manufacturing through continuous processing.
Akiko Yabuuchi, Ph.D., Research Associate, Harvard Medical School, Children’s Hospital Boston, on a comparison of stem-cell research in Japan and the United States.
Joshua J. Spooner, PharmD, MS, Director of Clinical and Outcomes Services, Advanced Concepts Institute, University of the Sciences in Philadelphia, on the importance of producing high-quality dossiers for health plans.
Boro Dropulic, Ph.D., M.B.A, Founder and Chief Executive Officer, Lentigen, on the uses and advantages of his company’s Lentiviral Vector Platform.
Gerald Bernstein, M.D., F.A.C.P., Vice President for Medical Affairs, Generex Biotechnology, on Generex’s Oral-lyn insulin product and the advantages of buccal delivery.
Elizabeth Haanes, Ph.D., Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., on newly proposed Patent Office rules that would pose a hardship for the pharmaceutical industry.
Michael J. Krische, Ph.D., Professor, Department of Chemistry and Biochemistry, University of Texas at Austin, on a byproduct-free method of creating carbon-carbon bonds through hydrogenation.
William C. Crawford , Director of Industry Relations, Children’s Hospital Informatics Program, on creating a market for personally-controlled health records.
Gokhan S. Hotamisligil, M.D., Ph.D. , Chair, Department of Genetics and Complex Diseases, and J.S. Simmons Professor of Genetics & Metabolism, Harvard School of Public Health, on therapies at the interface of metabolic and inflammatory diseases.
Daniel J. Carlat, M.D. , Assistant Clinical Professor of Psychiatry, Tufts University School of Medicine, and Editor-in-Chief, The Carlat Psychiatry Report, on industry sponsorship of continuing medical education.
Paul Burn, Ph.D. , Senior Vice President of Research & Development, Juvenile Diabetes Research Foundation (JDRF), on JDRF’s increased focus on translational and clinical research.
Sara Rosenbaum, Chair, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, on the SCHIP reauthorization bill.
Frank Burroughs , President, Abigail Alliance for Better Access to Developmental Drugs, on his organization’s push for ACCESS legislation.
Pieter Muntendam M.D. , President and CEO, and Robert N. McBurney, Ph.D., Senior Vice President, Research & Development, and Chief Scientific Officer, BG Medicine, on creating biomarkers as decision tools for molecular medicine.
J. Scott Tarrant , VP of Business Development, Xceleron Inc., on prioritizing compounds with human PK data through microdosing studies.
Barry J. Schindler, Shareholder, Greenberg Traurig, LLP, on unresolved points of contention in the proposed patent reform bill.
Eileen Hilton, M.D. , President and CEO, Biomedical Research Alliance of New York (BRANY), on BRANY’s one-stop service for multi-center clinical trials.
Naomi Aronson, Ph.D. , Executive Director, Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center (TEC), on technology assessments and comparative effectiveness reviews.
Michael Milburn, Ph.D. , Chief Scientific Officer, Metabolon, Inc., on using metabolomics in biomarker discovery and compound profiling.
Stuart W. Peltz, Ph.D. , President and CEO, PTC Therapeutics, on his company’s approach of using small molecules to regulate protein synthesis.
Bruce W. MacLennan, Partner, Herrick Feinstein LLP, on negotiating licensing deals with biotech companies.
Daniel B. Ravicher , President and Executive Director, Public Patent Foundation, on challenging bad patents to serve the public interest.
Jacques E. Rossouw, M.D. , Chief of Women’s Health Initiative Branch, National Heart, Lung, and Blood Institute, NIH, on refining treatment recommendations for hormone therapy.
Wayne Koberstein , Consultant, on trends and developments among some of the key companies within the pharmaceutical industry.
William A. Sarraille , Partner, Sidley Austin LLP, on the potential impact of CMS’s proposed rules regarding Average Manufacturer Price (AMP) in Medicaid
Mark Kessel , Co-Founder and Managing Director, Symphony Capital, on Symphony Capital’s partnership approach to financing the development of early clinical-stage compounds.
William L. Warren , Partner, Sutherland Asbill & Brennan LLP, on Representative Waxman’s proposed bill on follow-on biologics.
Lynn E. Eccleston , Attorney, McGuire Woods LLP, on the ramifications of the Supreme Court’s decision on declaratory judgments in MedImmune v. Genentech.
Shin-Ichiro Imai, M.D., Ph.D. Assistant Professor, Molecular Biology and Pharmacology, Washington University School of Medicine, on research into Sir2 and longevity.
Kenneth A. Getz, Senior Research Fellow, Tufts Center for the Study of Drug Development, on factors affecting speed and efficiency in clinical development.
Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager of Drug Repositioning and Selection, Gene Logic, on Gene Logic’s drug repositioning business.
Gary P. Pisano, Professor, Harvard Business School, on his new book on the biotechnology industry, Science Business.
Richard P. Burgoon, Jr., CEO, Aeolus Pharmaceuticals, Inc., on catalytic antioxidants and Aeolus’ corporate strategy.
Marc Fisher, MD, Professor of Neurology, University of Massachusetts Medical School, on new approaches for clinical development of stroke therapies.
Eric Button, President and Managing Director, The BioMarker Group, on integrating biomarkers into drug development programs.
Alan Goldhammer, Associate Vice President Regulatory Affairs, Pharmaceutical Research and Manufacturers of America, on PhRMA’s views of the Institute of Medicine’s recommendations to improve drug safety.
Arthur M. Krieg, M.D., Senior Vice President, Research and Development, and Chief Scientific Officer, Coley Pharmaceutical Group, on Coley’s development of CpG oligonucleotide immunotherapeutics.
Brian P. Murphy, Partner, Morgan, Lewis & Bockius LLP, on unresolved issues in Hatch-Waxman settlement agreements.
Mihael H. Polymeropoulos, M.D., CEO, and Chip Clark, Chief Business Officer, Vanda Pharmaceuticals, on Vanda’s genomics-based approach to product differentiation in the market for CNS treatments.
Fumihiko Urano, M.D., Assistant Professor, University of Massachusetts Medical School, on the role of IRE1 in insulin biosynthesis in response to ER stress.
Bruce E. Schneider, Executive Vice President and Chief of Operations, Wyeth Research, on Wyeth’s adoption of a “learn and confirm” approach to clinical development.
Duane Thurman, Director, Prescription Drug Program, Washington State Health Care Authority, on the state’s preferred drug list and efforts to promote evidence-based, cost-effective prescribing behavior.
Craig Atwood, Assistant Professor, Department of Medicine, University of Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.
Hiromi Yoshikawa, Chairman and CEO, Otsuka America Pharmaceutical, Inc., on the expansion of Otsuka’s pharmaceutical business in the US.
Daniel L. Weiner, Senior Vice President, Software Products, Pharsight Corporation, on Pharsight’s CRADA with the FDA and the infrastructure required for modeling and simulation in clinical development.
Garo H. Armen, Chairman and CEO, Antigenics Inc., on Oncophage, an experimental cancer vaccine using heat shock proteins.
Donald A. Berry, Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, on the use of Bayesian statistical methods in clinical development.
John E. McDonough, Executive Director, Health Care For All, on new legislation designed to reduce the number of people without health insurance in Massachusetts.
Robert J. Feeney, Jr., President & CEO, MedVantx, on his company’s Sample Centers that dispense free generic drug samples.
Dr. Anthony Hayward, Director, Division of Clinical Research Resources, National Center for Research Resources, NIH, on a new Roadmap initiative to promote clinical research.
Dr. Steve E. Phurrough, Director, Coverage & Analysis Group, CMS, on National Coverage Determinations for Part B Drugs in Medicare.
Dr. Randall S. Stafford, Assistant Professor of Medicine, Stanford Prevention Research Center, on new research in off-label prescribing patterns.
Dr. Bruce Silver, VP of Global Product Development Services in Oncology, PRA International, on issues in cancer drug development.
Dr. John T. Santini, Jr., President, MicroCHIPS, Inc., on implantable devices for drug delivery.
Diana Conmy, Corporate Director of Market Insights at IMS Health, on key developments for the pharmaceutical industry in 2005.
Paul J. Hastings, President and Chief Executive Officer of Oncomed, Inc., on drugs to target cancer stem cells.
Dr. David Sinclair, Associate Professor of Pathology at Harvard Medical School, on the effects of SIR2 on the aging process.
Dr. Abner L. Notkins, Chief of Experimental Medicine for the National Institute of Dental and Craniofacial Research at the NIH, on the use of autoantibodies in predictive medicine.
Michael Valentino, Chief Consultant, PBM Strategic Healthcare Group, VA, on the VA�fs national formulary.
J.D. Kleinke, Chairman & Executive Director, Omnimedix Institute, on obstacles to the development of a viable HIT system.
Dr. Barry Davis, Principal Investigator & Director, ALLHAT Clinical Trials Center, on using the landmark ALLHAT results to change prescribing behavior.
Dr. Gerald Reaven, Professor Emeritus (Active) of Medicine, Stanford University, on insulin resistance syndrome.
Dr. Stanley Ip, Project Leader, and Dr. Peter Bonis, Primary Technical Expert, Tufts-New England Medical Center Evidence-based Practice Center, on the comparative effectiveness of treatments for gastroesophageal reflux disease.
Dr. Timothy Anderson, Senior Pharmaceutical Analyst, Prudential Equity Group, LLC, on pharmaceutical patent expirations in 2006.
Dr. Kazuko Nishikura, Professor, Gene Expression and Regulation Program, The Wistar Institute, on her research into RNA editing and microRNA.
Dr. Alice M. Rivlin, Senior Fellow in Economic Studies, The Brookings Institution, on the fiscal sustainability of Medicare spending.
James M. Karis, President & CEO, Entelos, Inc., on the role of in silico modeling in drug development.
Jerry Avorn, Professor of Medicine, Harvard Medical School, on academic detailing and physician prescribing behavior.
Kenneth I. Kaitin, Director, Tufts Center for the Study of Drug Development, on recent drug output trends.
Joan Alker, Senior Researcher, Georgetown Health Policy Institute, on Florida’s proposed changes to the state Medicaid program.
Joshua Shinoff, Licensing Officer, Office of Technology Licensing, on technology transfer at UC Berkeley.
John A. Scarlett, President and CEO, Tercica, on the company’s newly approved treatment for short stature.
Jean R. Slutsky, Director, Center for Outcomes and Evidence, on MMA provisions affecting the Agency for Healthcare Research and Quality.
Dara A. Corrigan, Partner, Arnold & Porter, on new MMA priorities for the Inspector General’s Office at HHS.
Larry Gold, CEO & Chairman of the Board, SomaLogic, Inc., on the uses of aptamer technology.
Larry D. Sasich, Staff Pharmacist, Public Citizen, on drug safety issues at the FDA.
Mark Heesen,President, National Venture Capital Association, on venture capital financing trends in the biotech industry.
Dr. John A. Gans, EVP and CEO, American Pharmacists Association, on the role of pharmacists in improving drug safety.
David Largaespada,Associate Professor, University of Minnesota Cancer Center, on a new method of cancer-gene identification using the Sleeping Beauty transposon.
Makoto Nishimura, President and CEO of Astellas Pharma US, Inc. on Astellas’s strategy in U.S. market.
Sharon Anglin Treat, Executive Director, National Legislative Association on Prescription Drug Prices, on state-level initiatives to reduce prescription drug prices..
Dr. Moriya Tsuji, Associate Professor, Aaron Diamond AIDS Research Center, Rockefeller University, on the discovery of new antigens that bind to the CD1d receptor and activate NKT cells.
Larry McComber, VP Contract and Program Services, Novation LLC, on GPO contracting for prescription drugs.
Robert K. Passikoff, Founder and President, Brand Keys, Inc., on DTC corporate and product brand promotion.
Jeffrey I.D. Lewis, Partner, Patterson Belknap Webb & Tyler LLP, on the impact of the Integra v. Merck decision on pharmaceutical research.
Shabbir Dahod, President and CEO, SupplyScape Corporation, on developing an electronic pedigree for the pharmaceutical supply chain.
Michael Rosen, Chairman and CEO, Immune Cell Therapy, Inc., on the life sciences hub in the Midwest.
Gary Zammit, President and CEO, Clinilabs, Inc., on progress in developing treatments for sleep disorders.
Frank M. Rapoport, Partner, McKenna Long & Aldridge LLP, on the BioShield legislation and the development of a biodefense industry.
Steve Powell, Vice President of Worldwide Sales, Phase Forward, Incorporated, on the use of electronic data capture in clinical trials
Christopher Watts, Staff Fellow, Center for Drug Evaluation and Research, FDA, on moving to real time release with PAT.
Daniel Devine, President and CEO, Acceptys, Inc., on shifting from humanized to fully-human monoclonal antibodies.
Alton C. Morgan, Chairman and President, InNexus Biotechnology, Inc., on the development of SuperAntibodies.
Paul Cusenza, Vice President, Alliance Management, Perlegen Sciences, Inc., on Perlegen’s approach to high-density, whole genome SNP genotyping.
Derek Guyton, Principal, Mercer Human Resources Consulting, on how employer-sponsored retiree drug benefits are being affected by the MMA.
Steven H. Sklar, Partner, Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision on declaratory judgment actions.
Vera Hassner Sharav, President, Alliance for Human Research Protection, on how industry practices in clinical trials have led to an erosion of public trust.
Maxine Gowen, Managing Partner, SR One, on the investment approach of a venture capital subsidiary of a major pharmaceutical company.
John Santa, Medical Director of the Center for Evidence-based Policy at Oregon Health and Science University, on state initiatives to create a transparent drug evaluation system for more cost-effective drug spending.
J. David Haddox, Vice President, Risk Management & Health Policy, Purdue Pharma, on a government-aided, multifaceted approach to reduce the potential for abuse of prescription pain treatments.
Mark Merritt, President and CEO, Pharmaceutical Care Management Association, on the role of pharmacy benefit managers in the Medicare prescription drug benefit.
Joseph S. McCracken, Vice President, Business Development, Genentech, Inc., on Genentech’s approach to R&D and commercialization partnerships.
Kathleen Jaeger, President and CEO, Generic Pharmaceutical Association, on the scientific advancements facilitating regulatory evaluations of biogenerics.
Richard C. Aulatta, President, R.C. Auletta and Co., on Merck’s handling of the Vioxx recall.
Michael Krensavage, Senior Vice President, Equity Research, Raymond James & Associates, on Schering-Plough’s turnaround strategy.
Richard D. Kelly, Senior Partner, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., on issues relating to authorized generics.
Jeffrey Aronin, Founder, President and COO, Ovation Pharmaceuticals, on Ovation’s niche market business strategy.
Nobuya Oka, Executive Vice President, Takeda Pharmaceuticals North America, on Takeda’s strategy in the U.S. market.
Reeta Roy, Vice President, Global Citizenship and Policy, Abbott Laboratories, on Abbott’s AIDS initiatives in developing countries.
Kevin Outterson, Associate Professor of Law, West Virginia University, on the impact of the Australia-U.S. Free Trade Agreement on the market for pharmaceuticals.
Vamsi K. Mootha, M.D., Assistant Professor, Harvard Medical School, on the team-science approach to biomedical research.
Michael M. Gottesman, M.D., Deputy Director for Intramural Research, NIH, on intramural research at the NIH.
Barry Greene, Chief Operating Officer, Alnylam Pharmaceuticals, on RNAi therapeutics.
Carl B. Feldbaum, President, Biotechnology Industry Organization (BIO), on the development of BIO and the biotech industry during his tenure.
Donald W. Moran, President, The Moran Company, on New York Attorney General Eliot Spitzer’s fraud suit against GlaxoSmithKline.
Frank F. Bilstein (Left), Partner, and Razmic S. Gregorian, Jr. (Right), Director, Simon-Kucher & Partners, on the impact of the Medicare legislation on the environment for drug pricing in the U.S.
Robert Monaghan (Left), CEO, and Lawrence K. Cohen (Right), Vice Chairman, Zyomyx Inc., on the use of protein chips in drug development.
Viren Mehta, Managing Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis merger .
John Rother, Director of Policy and Strategy, AARP, on the new Medicare drug discount cards and legislative reform priorities for Medicare.
Merrill Goozner, Journalist and Project Director, Center for Science in the Public Interest, on his new book, The $800 Million Pill.
Josef H. von Rickenbach, Chairman and CEO, PAREXEL International, on current trends in clinical development.
Scott Gottlieb, M.D.,Director of Medical Policy Development, FDA, on Mark McClellan’s tenure at the FDA. .
Wayne Koberstein, Contributing Editor, Contract Pharma, on globalization, consolidation, and pharmaceutical market strategies.
Barbara Yanni, Chief Licensing Officer and Vice President, Merck & Co., Inc., on Merck’s in-licensing activities.
Steven Rauscher, President and CEO, Genome Therapeutics, on the market launch of Factive.
Richard Trabert, Public affairs consultant and faculty member at Boston College’s Center for Corporate Citizenship, on social initiatives in the pharmaceutical industry.
Lowell E. Schnipper, M.D., Harvard Medical School Professor and Chief of Hematology and Oncology at Beth Israel Deaconess Medical Center, on synergies between new and existing treatments in oncology.
Soichi Matsuno, Chairman, Eisai Inc., on Eisai’s strategy in the U.S. market.
Donald O. Beers, Partner, Arnold & Porter, on polymorph patents.
Ken Araki, Pharmaceutical Industry Global Research Director, Nomura Securities International, on the forces shaping change in the pharmaceutical industry.
Jean-Paul Modde, Group President, Dendrite International, Inc., on new trends in CRM in the pharmaceutical industry.
Kevin Goodno, Commissioner, Minnesota Department of Human Services, on Minnesota’s initiatives toward prescription drug importation.
Preston Henske, Vice President, Bain & Company, on building a new business model in the pharmaceutical industry.
Kenneth S. Abramowitz, Senior Advisor, The Carlyle Group, on the impact of Medicare reforms on the HMO industry.
Anthony Robbins, M.D., Professor of Public Health, Tufts University School of Medicine, on Medicare reform in historical perspective.
Louis M. Solomon, Partner, Proskauer Rose LLP, on Hatch-Waxman reforms.
Sharon Treat, Senate Majority Leader, State of Maine, on Maine’s initiatives to lower the cost of prescription drugs.
Nick Naclerio, President, ParAllele BioSciences, on pushing the boundaries of high-throughput SNP genotyping.
Vibeke Strand, M.D., Adjunct Clinical Professor, Division of Immunology, Stanford University, on new treatment therapies for rheumatiod arthritis.
Christopher D. Hook, Director for RFID Market Development & Deborah H. Murphy, Life Sciences Market Development Manager, Zebra Technologies, on technologies for pharmaceutical supply chains.
Brian G. Atwood, Managing Director, Versant Ventures, on biotech venture capital investing and market cycles.
Glenn Rice, Vice President for Biopharmaceutical Sciences, SRI International, on bridging the gap from university research labs to clinical trials.
Eric Lindsey, Vice President for Business Development, PDI Inc., on salesforce outsourcing.
Jack Trout, President, Trout & Partners, Ltd., on product positioning through DTC advertising.
Tom Heyman, Executive Vice President for Business Development, Johnson & Johnson, on J&J’s in-licensing activities.
Paula Campbell Evans, Partner, Palmer & Dodge LLP, on the regulatory prospects for generic biologics.